Compare Bristol-Myers Squibb Co (BMY) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Roundhill NVDA WeeklyPay ETF — how do they compare? Bristol-Myers Squibb Co trades at $57.55 (market cap $116.30B), while Roundhill NVDA WeeklyPay ETF trades at $37.75. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Roundhill NVDA WeeklyPay ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| BMY | NVDW | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $62.37 | $53.42 |
52-Week Low | $42.60 | $31.88 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
NVDW trades at $35.81, down 4.66% over the past day, with technical indicators showing mixed signals—bullish oscillators but bearish moving averages. The stock has a history of frequent dividend payments, with recent payouts ranging from $0.21 to $0.48 per share. Key support is near $35, while resistance levels start at $38.
The outlook hinges on NVDW's ability to maintain its dividend stream amid market volatility. Risks include dependency on underlying asset performance and payout fluctuations. Upside potential exists if technical resistance is broken, but investors should monitor earnings stability and broader market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
